Binghamton University to host School of Pharmacy and Pharmaceutical Sciences Town Hall meeting

2016-02-02

BINGHAMTON, NY – Binghamton University will host a School of Pharmacy and Pharmaceutical Sciences Town Hall meeting at 1 p.m. Wednesday, Feb. 17, in Old Union Hall, on campus.  During the meeting, School of Pharmacy founding Dean Gloria Meredith will speak briefly about the future of the school and then open the floor to questions. This event is free and open to the public.

The $60 million School of Pharmacy and Pharmaceutical Sciences will be constructed on a 5.49-acre parcel at 96 Corliss Ave. in Johnson City. The 84,100 square-foot, four-story building will include state-of-the-art research and skills labs, a simulation facility, clean room, lecture halls, small group rooms, and offices for 33 faculty and 15 staff. The school’s full enrollment will include approximately 350 students in the PharmD program and an additional 30-40 PhD students. The school will open its doors to students in 2017, pending the award of pre-candidate status from the Accreditation Council for Pharmacy Education

Meredith has extensive experience in education, including course design and development, problem-based learning, small group (clinical case) learning, as well as more formal lecturing – and has been extensively involved in the professional education of surgeons, nurses and medical residents, receiving the top teaching award of the College of Surgeons in 1996.

She is a classical neuropharmacologist who has been continuously funded since 1994, including National Institutes of Health (NIH) funding since 2001. In 2013, Meredith won the Rosalind Franklin University’s top award for meritorious research. Her current research focuses on studies of neuroprotection and levodopa-induced dyskinesia in Parkinson‘s disease, and on basic mechanisms of drug craving in an animal model of amphetamine abuse.

She has more than 160 publications in top-quality journals, including co-authoring in 2007 an article in Nature that tested a potential neuroprotective drug for Parkinson‘s disease that has just completed Phase III clinical trials.

For more information, contact the Office of Student Affairs and Admissions, School of Pharmacy and Pharmaceutical Sciences, at jcward@binghamton.edu or call 607-777-5803. 

Last Updated: 9/17/13